* Deciphera Pharmaceuticals Inc DCPH.OQ reported a
quarterly
adjusted loss of 54 cents per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -60 cents. The mean expectation of
eleven analysts for the quarter was for a loss of 58 cents per
share. Wall Street expected results to range from -65 cents
to -50 cents per share.
* Revenue rose 32.9% to $48.30 million from a year ago;
analysts
expected $45.92 million.
* Deciphera Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 54 cents.
* The company reported a quarterly loss of $47.19 million.
* Deciphera Pharmaceuticals Inc shares had fallen by 8.5%
this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 2.6%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Deciphera
Pharmaceuticals Inc is $23.00
This summary was machine generated from LSEG data February 6 at
01:51 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.58 -0.54 Beat
Sep. 30 2023 -0.61 -0.58 Beat
Jun. 30 2023 -0.62 -0.57 Beat
Mar. 31 2023 -0.59 -0.60 Missed